Related Experiment Video

Updated: Feb 16, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.1K

Spleen Tyrosine Kinase Inhibition Modulates p53 Activity

Mohammad Althubiti1

  • 1Biochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.

Journal of Cell Death
|December 19, 2017
PubMed

Insights

Spleen tyrosine kinase (SYK) inhibition impacts p53 levels and cell death. Careful evaluation of SYK inhibitors is needed to prevent secondary malignancies, especially in solid tumors and chronic lymphocytic leukemia (CLL).

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Spleen tyrosine kinase (SYK) promotes B cell survival and proliferation, with inhibition showing promise in arthritis and chronic lymphocytic leukemia (CLL).
  • SYK overexpression in epithelial cancers can induce p53-dependent senescence, suggesting antineoplastic activity.

Purpose of the Study:

  • To investigate the role of SYK in DNA damage response and its impact on p53 activity.
  • To evaluate the effect of SYK inhibition on cell growth, cell death, and patient prognosis in solid tumors and CLL.

Main Methods:

  • Utilized chemical inhibitors of SYK in HCT116 and HT1080 cell lines.
  • Assessed SYK and p53 levels following DNA damage.
  • Correlated SYK expression with survival rates in solid tumor and CLL patient cohorts.

Main Results:

  • SYK is induced upon DNA damage, paralleling p53 levels.
  • SYK inhibition reduced p53 levels and modulated cell growth, decreasing cell death.
  • SYK expression correlated positively with survival in solid tumors but negatively in CLL patients.

Conclusions:

  • SYK inhibition modulates p53 expression and activity in specific cell lines.
  • Clinical use of SYK inhibitors requires careful consideration due to potential effects on cell death and secondary malignancy risk, particularly in solid tumors versus CLL.
Keywords:
HCT116HT1080SYKapoptosisp53

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

237
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K